Bone/Mineral Metabolism News

High serum sclerostin levels are independently correlated with low muscle mass in healthy Korean adults, according to findings published in Bone.

Endocrine Today has compiled a list of the top 10 news reports posted so far in of 2019.

Each month Endocrine Today reporters delve deep into a topic of current interest. These longform cover stories provide background and insights from leading researchers and clinicians. All of these features can be found under the opinion tab above and at the links below. Stories published so far in 2019 include emerging alternatives in thyroid cancer treatment, promising developments in beta-cell regeneration, questions about vitamin D’s effectiveness, and more.

Among a cohort of adults aged at least 60 years, participants with diabetes or high HbA1c became frailer more quickly than those without either condition, particularly if cardiovascular disease also was present, according to findings published in Diabetes Care.

Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily teriparatide followed by one subcutaneous injection of denosumab experienced a moderate gain in cortical bone mineral density at 18 months that was not observed among similar women who received the standard regimen of 18 months of teriparatide followed by 18 months of denosumab, according to findings published in the Journal of Bone and Mineral Research.

An estimated 40% to 50% of childhood cancer survivors will experience an endocrine disorder in their lifetime. The risk varies according to cancer treatment and can persist for decades after diagnosis.

Postmenopausal, normoglycemic women with a first-degree family history of diabetes have a higher bone mineral density at the lumbar spine and femoral neck when compared with similar women without a family history of the disease, according to findings published in Menopause.

For patients with osteoporosis, no drug treatment was associated with reduced mortality rates, according to a study published in JAMA Internal Medicine. These treatments should, therefore, only be recommended to decrease fracture risk.

Radius Health has initiated enrollment for a phase 3 clinical trial to assess the safety and efficacy of a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture, the company announced in a press release.

Identifying prevalent vertebral fractures on lateral spine images at the time of a bone density test influenced the subsequent use of osteoporosis therapies among patients, with the greatest impact observed among patients without osteoporosis by bone mineral density criteria, according to findings published in the Journal of Bone and Mineral Research.